Valeant Pharmaceuticals files a lawsuit aiming to force Allergan to hold a special shareholder meeting after hand-delivering 1,500 pages of documents showing shareholder support.
Valeant Pharmaceuticals and Pershing Square Capital Management reportedly plan to ask Allergan for a shareholder vote on their hostile takeover attempt, after a federal judge rules that Allergan's insider trading lawsuit won't delay the meeting.
Allergan reportedly solicits Salix Pharmaceuticals in a bid to stymie the $53 billion hostile takeover move by Valeant Pharmaceuticals and Pershing Square Capital Management.
The U.S. Securities & Exchange Commission is launching an insider trading probe into the hostile takeover bid for Allergan by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital, even as Allergan inks a $588 million deal for Taris Biomedical's Liris bladder drug and Ackman dangles the prospect of an IPO for Pershing Square.
Allergan uses the occasion of unrequited buyer Valeant Pharmaceuticals' latest financial report to drive home allegations that Valeant isn't being upfront about its business and accounting practices.
Healthcare giant Cardinal Health posts declines in its major drug business during its 4th quarter, but cost-control measures and gains in its smaller medical supplies division help beat analysts' estimates.
Ohio healthcare giant Cardinal Health (NYSE:CAH) got no Wall Street love after posting estimate-beating earnings today.
Illinois healthcare giant Baxter sells its commercial vaccines division ahead of a larger transformation that will split its medical products and pharmaceuticals businesses into separate entities.
Baxter (NYSE:BAX) agreed to offload its commercial vaccines business to pharmaceutical rival Pfizer (NYSE:PFE) for $635 million in cash.